目的 观察支原体肺炎患儿采取阿奇霉素联合孟鲁司特钠治疗的临床效果及其对患儿肺功能、免疫功能和炎性因子的影响。方法 选取中国人民解放军联勤保障部队第九八九医院2023年1月-2023年12月的306例支原体肺炎患儿，运用随机数字表法将纳入患儿分为阿奇霉素组153例和联合组153例。阿奇霉素组患儿采取注射用阿奇霉素10 mg/kg静滴，联合组在阿奇霉素组用药方案基础上加用孟鲁司特钠咀嚼片，口服给药，比较两组临床疗效、肺功能指标[用力肺活量(forced vital capacity，FVC)、呼气峰流速值(peak expiratory flow rate，PEF)、第1秒用力呼气的容积(volume of forced exhalation at 1 second，FEV1)]、临床症状改善状况、炎性因子指标[血清白细胞计数、C反应蛋白(C-reactive protein，CRP)、降钙素原(procalcitonin，PCT)]、免疫功能指标(免疫球蛋白IgA、IgM、IgG)水平。结果 治疗后，联合组总有效率为96。08％，显著高于阿奇霉素组的79。74％(P＜0。05);治疗后，联合组发热、咳嗽、喘息及肺部湿啰音等消退时间均短于阿奇霉素组(P＜0。05);联合组FVC、FEV1、PEF均高于阿奇霉素组，血白细胞计数、CRP、PCT、IgA、IgM、IgG水平均低于阿奇霉素组(P＜0。05)。治疗期间，联合组不良反应发生率(9。80％)略高于阿奇霉素组(6。54％)，但组间比较无统计学差异(x2=1。089，P=0。297)。结论 临床对支原体肺炎患儿的治疗，阿奇霉素联合孟鲁司特钠的治疗方案可提高患儿免疫力，进一步减轻机体炎性反应，从而改善患儿临床症状，促进肺功能的恢复，加快康复进程，进而提升临床疗效，具有较高的用药安全性。
Clinical observation of montelukast sodium combined with azithromycin therapy for mycoplasma pneumonia children
Objective To investigate the impact on lung function,inflammatory factors,and immune function in children with mycoplasma pneumonia treated by montelukast sodium combined with azithromycin.Methods Totally 306 children with mycoplasma pneumonia admitted to the 989th Hospital of the People's Liberation Army Joint logistic Support Force from January 2023 to December 2023 were selected.They were divided into an azithromycin group and combination group using the random number table method,153 cases in each group.The clinical efficacy,improvement of clinical symptoms,lung function indicators[forced vital capacity(FVC),volume of forced exhalation at 1 second(FEV,),peak expiratory flow rate(PEF)],inflammatory factor indicators[serum white blood cell count,C-reactive protein(CRP),procalcitonin(PCT)],and immune function indicators[immunoglobulin A(IgA),IgM,IgG]in the two groups were compared.Results The total effective rate after treatment of the combination group(96.08％)was signifi-cantly higher than that of the azithromycin group(79.74％,P＜0.05).After treatment,the disappearance time of fe-ver,cough,wheezing,and lung moist rales in the combination group was shorter than those in the azithromycin group(P＜0.05).The FVC,FEV1,and PEF levels in the combination group were higher than those in the azithromycin group,and the serum levels of white blood cell count,CRP,PCT,IgA,IgM,and IgG were lower than those in the az-ithromycin group(P＜0.05);during treatment,the incidence of adverse reactions in the combination group was 9.80％,and was slightly higher than 6.54％in the azithromycin group,with no significant difference between the two groups(x2=1.089,P=0.297).Conclusion The combination treatment of montelukast sodium and azithromycin for mycoplasma pneumonia children can further alleviate the inflammatory reactions,enhance the body's immune system,quickly improve clinical symptoms,promote lung function recovery,accelerate the recovery process,and ultimately en-hance clinical efficacy,and it has high drug safety.
NETL
NSTL
万方数据
